tiprankstipranks
Trending News
More News >

Hoth Therapeutics Advances HT-001 for Cancer Treatment

Story Highlights
  • Hoth Therapeutics develops HT-001 to treat skin toxicities from EGFR inhibitors.
  • Preclinical and Phase 2a studies show HT-001 reduces skin toxicities and maintains cancer treatment efficacy.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Hoth Therapeutics Advances HT-001 for Cancer Treatment

Don’t Miss TipRanks’ Half-Year Sale

Hoth Therapeutics ( (HOTH) ) has provided an announcement.

Hoth Therapeutics has announced the development of HT-001, a topical gel designed to treat cutaneous toxicities caused by EGFR inhibitors used in cancer treatment. Preclinical studies and preliminary data from an ongoing Phase 2a study show promising results, with significant reductions in skin toxicities and maintenance of cancer treatment efficacy. This development positions Hoth Therapeutics as a pioneer in addressing a significant unmet need in oncology, potentially improving patient outcomes and offering a novel solution for managing dermatological side effects in cancer patients.

The most recent analyst rating on (HOTH) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.

More about Hoth Therapeutics

Hoth Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for unmet medical needs. The company is primarily engaged in creating treatments for dermatological conditions, particularly those induced by cancer therapies, such as epidermal growth factor receptor inhibitors (EGFRIs).

Average Trading Volume: 1,189,264

Technical Sentiment Signal: Buy

Current Market Cap: $15.98M

Learn more about HOTH stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1